Kornimate/medical-research-clean huggingface dataset:
lipid-lowering effects of gefarnate in statin-treated coronary heart disease patients with residual hypertriglyceridemia

Conditions: Coronary Artery Disease

Summary: dyslipidemia is an independent risk factor for cardiovascular events. statins have become the cornerstone for the prevention and treatment of atherosclerotic vascular diseases. however, after the comprehensive control of the traditional risk factors, including unhealthy lifestyle, hypercholesterolemia, hypertension, hyperglycemia and obesity, there is still a high risk of residual cardiovascular disease in patients with dyslipidemia. triglyceride elevation is the most common type of dyslipidemia and constitutes an important component of cardiovascular residual risk. the geraniol has a variety of pharmacological effects, such as anti-inflammatory, antioxidant, regulating cell apoptosis. recent studies have confirmed that geraniol plays an important role in regulating glucose and lipid metabolism, and may have a synergistic role with statins. gefarnate tablets is a kind of anti-ulcer and gastritis treatment. it can increase the defense ability of gastric mucosa by improving the prostaglandin level and the concentration of amino hexose in the gastric mucosa. geraniol is the main components of gefarnate tablets. in the previous study, the investigators found that geraniol induced autophagy through the sirt1-ampk-mtor pathway and accelerated the degradation of triglycerides in liver cells, thus reducing the level of triglyceride in the serum of high fat diet mice. 6 patients with hyperlipidemia were received gefarnate tablets (100mg/ times, 3 times per day). a month later, the levels of serum triglyceride, total cholesterol, and low density lipoprotein cholesterol were decreased significantly. however, the above results need to be confirmed by the larger clinical research. therefore, the aim of this study is to evaluate the effect of gefarnate tablets on blood lipid levels in patients with hypertriglyceridemia and coronary heart disease treated with statins, provide more options for the treatment of lipid lowering treatment, reduce the risk of cardiovascular remnant, and improve the long-term prognosis of the coronary heart disease patients with residual hypertriglyceridemia.


Eligibility criteria:
inclusion criteria: * coronary artery disease * treatment with statins for more than 1 month * plasma triglyceride level more than 1.7mmol/l exclusion criteria: * atherosclerotic cardiovascular disease (ascvd) patients with high risk * patients with active liver disease or unexplained elevated levels of aminotransferase * patients with prostatic hypertrophy or those with prostaglandin drugs such as glaucoma * creatinine clearance \< 30ml/min * an allergy to any component of gefarnate tablets or statin
comparative study (double-blind) of mra for rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to investigate the clinical efficacy and safety of mra in a double-blind, parallel-group, controlled study using mra or methotrexate (mtx) in rheumatoid arthritis (ra) patients with mtx administered.


Eligibility criteria:
inclusion criteria * diagnosis of ra based on the 1987 classification criteria of the american college of rheumatology (acr) * disease duration of 6 months or more * treated with 8 mg/week of mtx for at least 8 weeks immediately preceding enrollment, and continued on this treatment up to initiation of the study drug * active disease at enrollment (less than 2 weeks before initiating treatment with a study drug), which is defined as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the japanese rheumatism foundation's drug evaluation committee and esr at least 30 mm/hr and crp not less than 1.0 mg/dl exclusion criteria * assessed as having class iv steinbrocker functional activity in the 4 weeks preceding treatment with the study drug * treated with infliximab, etanercept or leflunomide in the 12 weeks preceding treatment with the study drug * received any of the following therapies in the 2 weeks preceding initiation of treatment with the study drug. 1. administration of any dmard or immunosuppressant other than mtx 2. administration of corticosteroids exceeding 10 mg/day as prednisolone 3. dose escalation or initiation of corticosteroids * received any of the following therapies in the 4 weeks preceding treatment with the study drug 1. plasma exchange therapy 2. surgical treatment (operation, etc.)
effect of foot muscle energy technique in patients with diabetic neuropathy

Conditions: Diabetic Neuropathies

Summary: foot muscle energy technique and conventional physical therapy program administered in patients with type 2 diabetic neuropathy.

foot muscle energy technique and conventional physical therapy program administered in patients with type 2 diabetic neuropathy.

Eligibility criteria:
inclusion criteria: * participants (males and females) examined with non-insulin-dependent diabetes for ≥10 years determined by neurophysiological measurements were enrolled. * the participants regularly took their diabetes medications during the assessment and treatment period. * the use of any sedatives or anticonvulsants was contraindicated for all participants. exclusion criteria: • uncontrolled non-insulin dependent diabetes and diagnosed for \< 10 years, neural, muscular, and skeletal system deformities; radiculopathy; and psychiatric disorders.

Keywords: diabetic neuropathy foot muscle energy technique isometric muscle strength motor nerve conduction velocity study
special investigation (all case survey) in patients with juvenile idiopathic arthritis

Conditions: Arthritis, Juvenile Rheumatoid

Summary: this study of humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: * unknown adverse drug reactions (especially important adverse drug reactions) * incidence and conditions of occurrence of adverse reactions in the clinical setting * factors that may affect the safety and effectiveness of humira


Eligibility criteria:
inclusion criteria: * all patients with juvenile idiopathic arthritis who are not responding well to conventional therapy and receive humira will be enrolled in the survey exclusion criteria: * contraindications according to the package insert * patients who have serious infections * patients who have tuberculosis * patients with a history of hypersensitivity to any ingredient of humira * patients who have demyelinating disease or with a history of demyelinating disease * patients who have congestive cardiac failure

Keywords: arthritis, juvenile rheumatoid
efficacy of three antibiotic protocols for aggressive periodontitis treatment

Conditions: Aggressive Periodontitis

Summary: the aim of the present study is to evaluate the clinical and microbiological efficacy of moxifloxacin or amoxicillin plus metronidazole in one-stage scaling and root planing in treating generalized aggressive periodontitis. forty five subjects will be randomly allocated to 3 treatment groups. subgingival plaque samples will be analysed for cultivable bacteria. the primary outcome variable to determine the superiority of one treatment over the others would be differences between groups for means cal changes at 6 months post-treatment. secondary outcome variables include differences between therapies for the mean changes in the mean levels of pd and the proportion of bop.


Eligibility criteria:
inclusion criteria: * subjects ≤30 years of age * minimum of six permanent teeth, with at least one site each with probing depth (pd) and clinical attachment level (cal) ≥5 mm and a minimum of six teeth other than first molars and incisors with at least one site each with pd and cal ≥5 mm. exclusion criteria: * diabetes * cardiovascular diseases * immunological disorders or any other systemic disease that could alter the course of periodontal disease. * pregnant or nursing women * smoking * allergy to amoxicillin, metronidazole, fluoroquinolones or moxifloxacin * consumption of systemic antimicrobials or anti-inflammatory drugs in the last 6 months * periodontal therapy during the last 6 months
effects of nasal administration of dexmedetomidine on pre-anesthesia sedation, intraoperative brain electrical activity, and incidence of agitation during recovery in children

Conditions: Preoperative Anxiety; Emergence Agitation

Summary: pre - operative anxiety and emergence agitation are common issues among pediatric patients, which have various influences on the recovery progress and prognosis of children. nasal administration of dexmedetomidine is a convenient and non - invasive sedation technique for children. this technique can reduce the incidences of pre - operative anxiety and emergence agitation. however, there are few studies on the effect of dexmedetomidine on intraoperative electroencephalographic activities. in view of this, the investigators elaborately designed a prospective, multi - center, large - sample - sized, double - blind, randomized - controlled clinical trial. this trial aims to provide a basis for drug selection in pediatric anesthesia, ensuring the safety and comfort of pediatric anesthesia. the investigators plan to select 627 participants who will undergo minor surgeries under general anesthesia. thirty minutes before the surgery, dexmedetomidine or normal saline will be administered nasally to these participants. before the surgery, the anxiety degree and sedation score of the participants will be assessed; during the surgery, the cooperation degree of patients during anesthesia induction will be evaluated and electroencephalographic monitoring will be carried out; after the surgery, the incidence of emergence agitation, the recovery time and the analgesic score of the participants will be assessed. throughout the whole process, the occurrence of adverse reactions of participants will be fully monitored, and the adverse reactions will be timely recorded and treated.


Eligibility criteria:
inclusion criteria: * 2≤ age ≤6 years old, gender is not limited; * asa anesthesia grade i \~ ii; ③ for children who intend to undergo minor surgery under general anesthesia (including but not limited to minor surgery such as ent surgery and hernia surgery), the operation duration is expected to be no more than 2 hours; ④ family members agree to participate in the study and voluntarily sign informed consent; exclusion criteria: * respiratory tract infection occurs within 4 weeks before surgery; * potential or other contraindications to general anesthesia; * there are nasal diseases, nasal bleeding, sinusitis, nasal polyps and other conditions that affect nasal absorption; ④ heart, liver, kidney and other vital organ dysfunction or blood system diseases; * allergy or intolerance to dexmedetomidine or other α2-adrenergic receptor agonists; * patients with mental illness or neurological diseases; * unable to complete the test, the child's guardian refused to participate; ⑧ have participated in other clinical trials or need to participate in other clinical trials during the study period; ⑨ other reasons that the researchers consider inappropriate to participate in this study.
cross-sectional survey on patients with urinary tract infections in puy-de-dôme : epidemiology of recurrent urinary tract infections and risk factors

Conditions: Urinary Tract Infections

Summary: urinary tract infections (uti) are an important part of infectious diseases. for some patients, those infections are recurrent and have many consequences such as altered quality of life, recurrent symptoms, antibiotics overuse... the primary purpose of this study is to estimate the proportion of patients in puy-de-dôme with recurrent urinary tract infections among patients with at least one uti during 2019. the secondary purposes are : characteristics of patients with recurrent uti, by sex ; determine predictive factors of recurrent uti, by sex ; describe bacterial ecology of recurrent uti and the proportion of multi-resistant bacteria.


Eligibility criteria:
inclusion criteria: * patient from 18 years old * affiliated to the french healthcare system * with at least one urinary tract infection during year 2019 * has accepted email contact with cpam 63 (caisse primaire d'assurance maladie du puy-de-dôme) exclusion criteria: * pregnancy during year 2019 * none urinary tract infection reported in 2019
laser disinfection in periprosthetic joint infection

Conditions: Periprosthetic Joint Infections

Summary: the eradication of biofilms from infected implants is still an unsolved challenge. the high-energy light beam of an er:yag laser causes rapid heating and explosive ablation of tissue. in this study we test the suitability of this laser for the removal of biofilms from infected implant surfaces.

infections after joint arthroplasties represent a devastating and progressively escalating complication with increased morbidity and mortality. the eradication of biofilms from infected implants is still an unsolved challenge. the high-energy light beam of an er:yag laser causes rapid heating and explosive ablation of tissue. in this study the investigators test the suitability of this laser for the removal of biofilms from infected implant surfaces. methods in this prospective study, acute or early hematogenous periprosthetic joint infections (pjis) will be treated with the modified procedure of debridement, antibiotics, laser irradiation and implant retention (dalir). the investigators compare the completeness of biofilm removal from the implant surface with mechanical cleansing alone and the additional use of er:yag laser light. therefore, the investigators will obtain swab cultures from the implants on three distinct occasions: post-arthrotomy, subsequent to mechanical cleansing, and after er:yag laser irradiation. the investigators also compare the success rate of the dalir procedure with the international literature. results the investigators expect, that the prevalence of viable microorganisms obtained from implant surfaces through swab cultures will be considerably diminished after additional er:yag laser therapy in comparison to only mechanical cleaning with lavasurge®. the investigators hope to reach a higher healing rate in relation to comparable studies. conclusion if the hypothese is correct, the investigators will recommend the use of er:yag laser irradiation as an additional tool for disinfection of metal implants in pjis whenever a dair procedure seems to be beneficial.

Eligibility criteria:
inclusion criteria: * patients with periprosthetic joint infection (pji) that will be treated with a debridement, antibiotics, and implant retention (dair) procedure exclusion criteria: * when a dair procedure seems not beneficial in a pji case.

Keywords: er:yag laser biofilm removal periprosthetic joint infections (pji) dair laser disinfection
effects of affroneye®/ crocuvis+® on dry eye syndrome

Conditions: Dry Eye Syndrome

Summary: previous research has demonstrated the effectiveness of affroneye® / crocuvis+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. the main objective of this study is to compare the results of clinical tests that evaluate signs and symptoms for the diagnosis of dry eye, between two groups (some that take the dietary supplement and others a placebo), in a sample of university workers and students who suffer from dry eye.


Eligibility criteria:
inclusion criteria: * have dry eye according to the diagnostic criteria established by the tear film and ocular surface society (tfos) dry eye workshop (dews). exclusion criteria: * pathology of the anterior ocular surface under treatment (such as conjunctivitis, keratitis, among others). * take any type of dietary supplements, with or without botanical components in the last month. * pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant.
the confucius oral protein supplementation trial

Conditions: Intensive Care Unit Acquired Weakness; Critical Illness

Summary: study the effect of 6-weeks porcine protein supplementation vs isocaloric comparator (carbohydrate) on functional outcomes in post icu-patients. patients will be included at icu discharge. included patients will receive the supplements twice daily (morning and afternoon), starting at the first day at the general ward. to the best of our knowledge, a study on protein supplementation in the post-icu period to address its effect on functional outcomes is lacking.

patients discharged from the intensive care unit frequently suffer from post intensive care syndrome. this syndrome is characterized by muscle weakness and physical disabilities besides neurocognitive and psychological disturbances. studies have shown that protein requirements in the post-icu phase are often not met. furthermore, protein supplementation in other patient groups have shown beneficial effects. however, a study on protein supplementation during the post-icu period is lacking. this study aims to investigate the effect of protein supplementation on functional outcomes in post-icu patients.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. living at home before hospital admission 3. minimum icu stay of 72 h 4. informed consent exclusion criteria: 1. mrc sum score ≤24 or 48≥ at icu discharge 2. barthel index \<14 before icu admission 3. chronic home ventilation 4. mitochondrial or muscle disease or pareses 5. serum creatinine \> 173 mcmol/l (renal dysfunction) 6. treatment limitations: dnr, no icu readmission or palliative care 7. inclusion in another intervention trial since icu admission 8. intolerance or allergy (for study products) 9. people living in a nursing home before hospital admission 10. chronic organizing pneumonia or pulmonary interstitial fibrosis 11. inflammatory bowel disease 12. diabetes mellitus pharmaceutical medication at icu admission 13. underlying disease in which in the eyes of the attending physician, the protein or carbohydrate supplement could form a risk for the patient. 14. pregnancy

Keywords: functional outcomes proteins intensive care unit
school support as structural hiv prevention for adolescent orphans in kenya

Conditions: HIV

Summary: the purpose of this study is to test whether school support can keep adolescent kenyan orphans in school, reduce sexual risk behaviors, and prevent hiv /hsv-2 infection.

this study examines the impact of school support as a structural intervention, tested among adolescent orphans in siaya district, nyanza province, kenya. aims for the proposed study are: 1) to experimentally test whether providing comprehensive school support to kenyan orphaned boys and girls will reduce school dropout, reduce sexual risk behaviors, and prevent hiv/hsv-2 infection; 2) to conduct a process evaluation of the implementation of the program; and 3) to conduct comparative cost effectiveness analyses, specifying the intervention's cost and return on investment as evidenced by cost per unit improvement in the primary outcomes of school enrollment, delay of sexual debut and prevention of risk behaviors and hiv/hsv-2 infection, as well as by gains in health-related quality of life.

Eligibility criteria:
inclusion criteria: * orphan (one or both parents deceased) * in grade 7 or 8 in a primary school participating in the study

Keywords: hiv prevention hsv-2 schooling kenya orphans school support
broadband light for the treatment of dry eye disease

Conditions: Dry Eye Syndromes; Meibomian Gland Dysfunction

Summary: the investigators will be evaluating the use of broadband light in dry eye and meibomian gland dysfunction.

broadband light (bbl) is a widely used treatment for improvement of inflammatory dermatologic conditions such as acne and rosacea, and may have similar therapeutic benefits on the treatment of dry eye disease by targeting inflammation of the eyelids. the investigators propose a prospective study to determine the safety and efficacy of bbl treatment on patients with dry eye disease and meibomian gland dysfunction. each participant will have three treatments of bbl at monthly intervals to the cheek and periorbital area with subsequent follow up. measured endpoints will include signs and symptoms of dry eye control including full ophthalmic exam, dry eye diagnostic testing, photographs, and standardized questionnaires.

Eligibility criteria:
inclusion criteria: * fitzpatrick skin type i-v * must be diagnosed with dry eye disease (ded) and meibomian gland dysfunction (mgd) * persistent dry eye signs and or symptoms after at least one prior ded treatment modality exclusion criteria: * prior intense pulsed light treatment for ded within the past six months * prior meibomian gland treatment with a device for ded within the past three months * history of trauma-induced ocular surface disease (thermal burns, chemical burns) * subject is pregnant * history of seizures * having significant unprotected sun exposure within the treatment area * use of accutane within the last six months * use of doxycycline in the last 1 month * allergy to proparacaine or lidocaine * having active herpes simplex virus infection within the treatment area * laser eye surgery (lasik) within the past twelve months * history of abnormal response to sunlight * having an active medical condition that may affect normal healing * having active infections or compromised immune system * history of basal cell carcinoma in the treatment area within the past twelve months * history of keloid scar formation

Keywords: dry eye blepharitis meibomian gland dysfunction intense pulsed light